SOLIGENIX, INC. — Director's Dealing 2007

Aug 14, 2007

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DOR BIOPHARMA INC (DORB)
CIK: 0000812796
Period of Report: 2007-08-10

Reporting Person: MYRIANTHOPOULOS EVAN (Director, Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2007-08-10	Stock Options (Right to Buy)	$0.47	A	550000	Acquired	2017-08-09	Common Stock (550000)	Direct

Footnotes

F1: The stock options were granted at an exercise price of $0.47 per share, which is a 68% premium to the Company?s common stock price of $0.28 on August 10, 2007. The stock options, which are for a term of 10 years from the date of grant and subject to earlier termination upon the occurrence of certain events related to termination of employment, vest at the rate of 25% immediately and 25% per year for 3 years.